DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.11
−5.26%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$18.03
From 52W high−36.11%
Volume4.84M
Market cap$3.20B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$18.03
From 52W high
−36.11%
Volume
4.84M
Market cap
$3.20B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.7x
P/E (TTM)
—
RSI (14)
22.5
MomentumView details →
1D Return
−5.26%
YTD Return
−12.48%
SummaryUpdated Jun 1, 2026
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The company went public in September 2020 and focuses exclusively on developing innovative therapeutics for genetically driven muscle diseases. Dyne operates as a specialized muscle disease company, leveraging its proprietary FORCE platform technology to advance potential treatments for rare and devastating muscular conditions that currently have limited or no therapeutic options.
Similar companies
Latest newsMore news →
Shares of Dyne Therapeutics and Sarepta Therapeutics fell on Tuesday after Novartis' muscle disease drug failed a trial, raising investor concerns about similar therapies.12d agoDyne Therapeutics received U.S. FDA clearance of its Investigational New Drug application for DYNE-302 in facioscapulohumeral muscular dystrophy.54d agoThe U.S. FDA accepted for review the Biologics License Application for Dyne Therapeutics' z-rostudirsen for Duchenne muscular dystrophy amenable to exon 51 skipping, granting priority review with a PDUFA target action date of January 21, 2027.62d ago